Atossa Therapeutics (NASDAQ:ATOS) Rating Reiterated by HC Wainwright

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday, Marketbeat.com reports. They currently have a $4.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 196.30% from the company’s previous close.

ATOS has been the subject of a number of other research reports. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Atossa Therapeutics in a report on Friday, January 12th.

Atossa Therapeutics Stock Down 12.3 %

ATOS opened at $1.35 on Tuesday. Atossa Therapeutics has a 52 week low of $0.59 and a 52 week high of $2.31. The business has a 50 day moving average price of $1.37 and a two-hundred day moving average price of $0.98. The company has a market cap of $169.16 million, a PE ratio of -5.63 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, April 1st. The company reported ($0.06) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Atossa Therapeutics will post -0.28 EPS for the current fiscal year.

Insider Buying and Selling at Atossa Therapeutics

In related news, Director Jonathan Finn acquired 25,000 shares of Atossa Therapeutics stock in a transaction that occurred on Wednesday, April 10th. The stock was purchased at an average price of $1.77 per share, for a total transaction of $44,250.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at $44,250. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 7.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP increased its holdings in Atossa Therapeutics by 29.3% during the 4th quarter. GSA Capital Partners LLP now owns 449,082 shares of the company’s stock valued at $395,000 after acquiring an additional 101,690 shares in the last quarter. Northern Trust Corp increased its stake in shares of Atossa Therapeutics by 6.2% during the 4th quarter. Northern Trust Corp now owns 227,922 shares of the company’s stock worth $201,000 after purchasing an additional 13,280 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $98,000. UBS Group AG acquired a new position in shares of Atossa Therapeutics during the 3rd quarter worth approximately $25,000. Finally, XTX Topco Ltd purchased a new stake in Atossa Therapeutics in the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.